Quantitative study on the correlation between p53 gene mutation and its expression in endometrial carcinoma cell lines

Mutant p53 protein is not degradated but accumulates in the nuclei. However, the relation between p53 gene mutation and quantity of p53 protein has not been clarified yet in endometrial carcinoma. We investigated the correlation between p53 gene mutation and its protein expression quantitatively using 11 cell lines of endometrial adenocarcinoma, endometrioid type and two serous-type cell lines. To examine p53 mutation, PCR-SSCP analysis in exon 5 to 8 and direct sequence were carried out. p53 expression was determined by immunocytochemistry and immunoblotting. The percentage of positive staining in the nuclei by immunocytochemistry was calculated as a labeling index (LI). The amount of p53 detected by immunoblotting was expressed as a comparative value of Ishikawa cells. Point mutation of p53 gene was detected in four of 11 (36.4%) cell lines of endometrioid adenocarcinoma, and all two of serous adenocarcinoma. There was a significant positive correlation between p53 LI and p53 values. The LI and the values of p53 were significantly higher in the mutant group than the wild one, thus showing a quantitative correlation between p53 protein expression and p53 gene mutation in endometrial carcinoma cell lines. It is plausible that immunohistochemical analysis of p53 could be qualified to be a convenient indicator of p53 gene mutation on clinical materials, if p53 LI is more than 40 (M-SD in mutant p53).

p53; Endometrial carcinoma; Mutation; Immunoblotting; Immunocytochemistry; HEC-1-A; Ishikawa

[1] Miller C., Mohandas T., Wolf D., Prokocimer M., Rotter V., Koeffler H. P.: "Human p53 gene localized to short arm of chromosome 17". Nature, 1986, 319, 783.

[2] Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C.: "Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis". Cancer Res., 1994, 54, 4855.

[3] Ashcroft M., Vousden K.H.: "Regulation of p53 stability". Oncogene, 1999, 18, 7637.

[4] Kubbutat M. H. G., Vousden K. H.: "Keeping an old friend under control: Regulation of p53 stability". Mot. Med. Today, 1998, 4, 250.

[5] Athanassiadou P., Petrakakou E., Liossi A., Nakopoulou L., Zerva C., Dimopoulos A., Athanassiades P.: "Prognostic Significance of p53, bcl-2, and EGFR in Carcinoma of the Endometrium". Acta cytol., 1999, 43, 1039.

[6] Reinartz J.J., George E., Lindgren B.R., Niehans G.A.: "Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and correlation with survival and known predictors of survival". Human Pathol., 1994, 25, 1075.

[7] Enomoto T., F ujita M., Inoue M., Rice J. M., Nakajima R., Tanizawa O., Nomura T.: "Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterin endometrium". Cancer Res., 1993, 53, 1883.

[8] Kohler M. F., Berchuck A., Davidoff A. M., Humphrey P. A., Dodge R. K., Iglehart J. D. et al.: "Overexpression and mutation of p53 in endometrial carcinoma". Cancer Res., 1992, 52, 1622.

[9] Salvesen H.B., Iversen O.E., Akslen L.A.: "Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: A population-based endometrial carcinoma study". J. Clin. Oncol., 1999, 17, 1382.

[10] Lax S.F., Kendall B., Tashiro H., Slebos R. J. C., Ellenson L. H.: "The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma evidence of distinct molecular genetic pathways". Cancer, 2000, 88, 814.

[11] Ito K., Sasano H., Matunaga G., Sato S., Yajima A., Nasim S., Garret C. T.: "Correlations between p21 expression and clinicopathological findings, p53 gene and patients with endometrial carcinoma". J. Pathol., 1997, 183, 318.

[12] Niwa K., Murase T., Morishita S., Hashimoto M., ltoh N., Tamaya T.: "p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status". Cancer Detec. Prev., 1999, 23, 147.

[13] Stewart R. L., Royds J. A., Burton J.L., Heatley M. K., Wells M.: "Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein". Histopathology, 1998, 33, 440.

[14] Kuramoto H., Nishida M., Morisawa T., Hamano M., Hata H., Kato Y. et al.: "Establishment and characterization of human endometrial cancer cell lines". Annals N. Y. Acad. Sci., 1991, 622, 402.

[15] Uchida T., Wada C., Shitara T., Egawa S., Koshiba, K.: "Infrequent involvement of p53 gene mutations in the tumorigenesis of Japanese prostate cancer". Br. J. Cancer, 1993, 68, 751.

[16] Bodner S. M., Minna J. D., Jensen S. M, D'Amico D., Carbone D., Mitsudomi T. et al.: "Expression of mutant p53 protein in lung cancer correlates with the class of p53 gene mutation". Oncogene, 1992, 7, 746.

[17] Shahin M. S., Hughes J. H., Sood A. K., Buller R. E.: "The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma". Cancer, 2000, 89, 2006.